1
|
Singla P, Luxami V, Paul K. Triazine-benzimidazole hybrids: anticancer activity, DNA interaction and dihydrofolate reductase inhibitors. Bioorg Med Chem 2015; 23:1691-700. [PMID: 25792141 DOI: 10.1016/j.bmc.2015.03.012] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Revised: 03/02/2015] [Accepted: 03/03/2015] [Indexed: 10/23/2022]
Abstract
A new series of triazine-benzimidazole hybrids has been synthesized with different substitution of primary and secondary amines at one of the position of triazine in moderate to good yields. These compounds were evaluated for their inhibitory activities over 60 human tumor cell lines at one dose and five dose concentrations. Compounds 6b, 8 and 9 showed broad spectrum of antitumor activities with GI50 values of 9.79, 2.58 and 3.81μM, respectively. DNA binding studies also indicated strong interaction properties of these compounds. These synthesized compounds also showed inhibition of mammalian dihydrofolate reductase (DHFR). Compound 6b was depicted as the most active member of DHFR inhibitor with IC50 value of 1.05μM. Molecular modelling studies were used to identify the stabilized interactions of Compound 6b within the active site of enzyme for DHFR.
Collapse
Affiliation(s)
- Prinka Singla
- School of Chemistry and Biochemistry, Thapar University, Patiala 147001, India
| | - Vijay Luxami
- School of Chemistry and Biochemistry, Thapar University, Patiala 147001, India
| | - Kamaldeep Paul
- School of Chemistry and Biochemistry, Thapar University, Patiala 147001, India.
| |
Collapse
|
4
|
Yan H, Kerns JK, Jin Q, Zhu C, Barnette MS, Callahan JF, Hay DWP, Jolivette LJ, Luttmann MA, Sarau HM, Ward KW, Widdowson KL, Wan Z. A Highly Convergent Synthesis of 2‐Phenyl Quinoline as Dual Antagonists for NK2 and NK3 Receptors. SYNTHETIC COMMUN 2006. [DOI: 10.1080/00397910500281234] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Hongxing Yan
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Jeffrey K. Kerns
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Qi Jin
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Chongjie Zhu
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Mary S. Barnette
- b Department of COPD Biology , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - James F. Callahan
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Douglas W. P. Hay
- b Department of COPD Biology , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Larry J. Jolivette
- c Department of DMPK , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Mark A. Luttmann
- b Department of COPD Biology , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Henry M. Sarau
- b Department of COPD Biology , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Keith W. Ward
- c Department of DMPK , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Katherine L. Widdowson
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| | - Zehong Wan
- a Department of Medicinal Chemistry , Respiratory & Inflammation Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals , King of Prussia , Pennsylvania , USA
| |
Collapse
|
5
|
Middleton DS, MacKenzie AR, Newman SD, Corless M, Warren A, Marchington AP, Jones B. Structure–activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-{2-[3-(substituted)-1-azetidinyl]-ethyl}-2-piperidones. Part 2: Improving oral absorption. Bioorg Med Chem Lett 2005; 15:3957-61. [PMID: 16039119 DOI: 10.1016/j.bmcl.2005.05.134] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2005] [Revised: 05/17/2005] [Accepted: 05/17/2005] [Indexed: 11/16/2022]
Abstract
A series of piperidone analogues of 1b-q, seeking replacements for the polar sulfamide moiety in clinical candidate UK-224,671 1a, possessing reduced H-bonding potential as a strategy to improve oral absorption, were prepared. These studies led to the successful identification of 1n, which demonstrated equivalent pharmacology and metabolic stability to 1a, and greatly improved oral absorption as assessed in rat PK studies.
Collapse
Affiliation(s)
- Donald S Middleton
- Department of Discovery Chemistry, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK.
| | | | | | | | | | | | | |
Collapse
|